medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2011, Number 2

<< Back Next >>

VacciMonitor 2011; 20 (2)

Adverse event surveillance of the polysaccharide meningococcal A and C vaccine during a vaccination campaign in Niger

Rodríguez MC, Cuevas IE, Mirabal M, Ruíz L

Language: Spanish
References: 17
Page: 17-23
PDF size: 294.83 Kb.


ABSTRACT

Immunoprophylaxis is the choice strategy for the prevention and control of meningococcal meningitis epidemics caused by Neisseria meningitidis serogroup A in the so-called meningitis belt of Africa, a disease that reaches high rates of morbidity and mortality. The lyophilized purified polysaccharide vaccine from Neisseria meningitidis serogroups A and C was produced as a result of a collaboration agreement between Finlay Institute, Center for Research, Development and Production of Vaccines, Cuba and the Institute of Technology and Bio- Immunobiologicals Manguinhos of Brazil, at the request of the World Health Organization to meet the needs of the vaccine in African countries in health emergencies. In the vaccination campaign carried out during an outbreak in Niger in 2009, a study of pharmacovigilance was conducted to describe the adverse events following the administration of this product to 303 037 people. Two methods were used to collect adverse events (spontaneous reporting and intensive search in hospitals). A total of 81 adverse events were reported, only 11% were under the category «induced by the vaccine» and considered «very probably related» to this. The results show that the vaccine used in the immunization campaign in Niger is safe, has low reactogenicity and their safety profile corresponds to that described in the sanitary medical registry in Brazil.


REFERENCES

  1. Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: Meningococcal disease. Vaccine 2006;24:4692-700.

  2. Djingarey MH, Noazin S, Préziosi MP, Lingani C, Tiendrebéogo S, Touré K, Kiari K, et al. A 20-year retrospective analysis of epidemic meningitis surveillance data in Burkina Faso, Mali and Niger. Presented at: International Pathogenic Neisseria Conference, September 2008; Rotterdam, The Netherlands. Disponible en: http://www.meningvax.org/files/ DjingareyIPNC2008 Retrospective_P166.pdf Consultado: 16 de mayo de 2011.

  3. World Health Organization. Meningitis in Chad, Niger and Nigeria: 2009 epidemic season. Weekly Epidemiological Record 2010;85 (8):57-68.

  4. Blog JANO. Medicina y Humanidades. Cerca de 2.000 muertos por meningitis en África subsahariana sólo en 2009 [versión electrónica]. Emergencia. Epidemia de meningitis en África, 2009. Disponible en: http://www.e-mergencia.com/foro/ archive/index.php/t-25953.html Consultado: 9 de mayo de 2011.

  5. World Health Organization. Outbreak news: Meningococcal disease, African meningitis belt. Weekly Epidemiological Record 2009;84(15):117–32.

  6. Bio-Manguinhos. Vacuna Polisacárida Meningocócica A y C (10 dosis). Prospecto. (Disponible en: http://www.fiocruz.br/bio/media/ bulas/vacinas/ BM_BUL_007_02_V_190624_ME10%20exp.pdf Consultado:: 20 de julio 2010.

  7. Ministerio de Salud Pública (Cuba). Regulación No 17-2008. Directrices para la investigación de los eventos adversos supuestamente atribuibles a la vacunación o inmunización (ESAVI). La Habana: MINSAP; 2008.

  8. Direction Générale de la Sante Publique, Direction de la Lutte contre la maladie. Cahier de Rapport mensuel d’Activités. PEV Systématique. République de Niger: Ministère de la Sante Publique; 2008.

  9. Organización Mundial de la Salud. Eventos adversos posvacunales (EAP): Evaluación de la causalidad. Disponible en: http://www.who.int/immunization_safety/en/ Consultado: 20 de julio de 2009.

  10. Collet JP, Mac Donald N, Ashman NC, Pless R & Advisory Committee on Causality Assessment Monitoring signals for vaccine safety: The assessment of individual adverse event report by and expert advisory committee. Bulletin of the World Health Organization 2000; 78(2):178-85.

  11. Bentsi-Enchill AD, Zongob I, Khamassia S, Pless R, Thombianod R, Tiéndrebéogo S, et al: Monitoring of adverse events during the 2003 mass vaccination campaing with the trivalent meningococal A/C/W135 polysaccharide vaccine in Burkina Faso. Vaccine 2007; 25S: A72–A78.

  12. World Health Organization. Niger, country mortality profile; 2009. Disponible en: http://www.who.int/whosis/mort/profile/ mort_afro_ner_niger.pdf . Consultado: 18 de febrero de 2010.

  13. -King WJ, Mac Donald NE, Wells G, et al. Total and functional antibody response to a quatrivalent meningococcal polysaccharide vaccine among children. Journal of Pediatrics 1996;28:196-202.

  14. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Manual de vigilância epidemiológica de eventos adversos pósvacinação / Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância Epidemiológica. Brasília: Ministério da Saúde; 2008

  15. De Abajo FC, Álvarez Requejo A, Ayani I, Carrillo JA, Carvajal A, Castillo JR, Cuchi T et al. Seguridad de la vacuna antimeningocócica A+C. Datos recogidos por el Sistema Español de Farmacovigilancia. Gaceta Sanitaria 1999;13 (6): 462-7.

  16. Saintonge F. Évaluation des reactions adverses associées au vaccine anti-méningococcique polysaccharideque de groupe A et de groupe C. Montréal, Canada: Direction de la Santé Publique de Montréal- Centre; 1995.

  17. Fiocruz. Polysaccharide meningococcal A and C vaccine is pre-qualified by the WHO; 2007. Disponible en: http:// w w w . f i o c r u z . b r / b i o _ e n g / c g i / c g i l u a . e x e / s y s / start.htm?infoid=550&sid=227 Consultado: 8 de julio de 2009.




2020     |     www.medigraphic.com